-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
RNAZ Stock Alert: The Breast Cancer Study News Sending TransCode Therapeutics Soaring Today
RNAZ Stock Alert: The Breast Cancer Study News Sending TransCode Therapeutics Soaring Today
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
TransCode Therapeutics (NASDAQ:RNAZ) stock is rocketing higher on Thursday as investors react to positive news from a breast cancer study.
Source: Bukhta Yurii / Shutterstock.com
According to a press release from the company, preclinical trial data for TTX-MC138 shows that it could be an effective treatment of breast cancer. TTX-MC138 is an RNA therapeutics treatment in development from the company.
Results from the preclinical study were published in Cancer Nanotechnology. It’s under the title “Radiolabeling and PET-MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastic lesions in a murine model of metastatic breast cancer.”
Michael Dudley, CEO of TransCode Therapeutics, said this in the release sending RNAZ stock higher today.
‘For TransCode, we believe this study further confirms the pharmacokinetic profile of TTX-MC138, supporting the viability of our platform for delivery of RNA-based therapy to metastatic solid tumors. Our preclinical data further suggest the therapeutic potential of TTX-MC138, and we look forward to our Phase 0 study which has the potential to establish clinical proof-of-concept for this therapy.”
So what does TransCode Therapeutics plan to do next? The company says it will file an exploratory investigational new drug application for TTX-MC138 in the first quarter of 2022. The goal is to use this for support of a Phase 0 study of its potential breast cancer treatment.
RNAZ stock is seeing heavy trading on today’s news. As of this writing, more than 147 million shares of the stock have changed hands. To put that in perspective, the company’s daily average trading volume is closer to 1.1 million shares.
RNAZ stock was up 91.4% as of Thursday afternoon.
We’ve got more of the latest stock market news investors need to know about below!
InvestorPlace offers deep dives into the stock market daily to assist traders. Today’s no different with us covering what thas shares of Plug Power (NASDAQ:PLUG), Novavax (NASDAQ:NVAX), and Roku (NASDAQ:ROKU) on the move. You can get all those details from the following links!
More Thursday Stock Market News
PLUG Stock: Why One Analyst Is Betting on Plug Power Hitting $33
NVAX Stock: The Big Covid-19 News Sending Novavax Shooting Higher
ROKU Stock Price Prediction: Why Analyst Sees Roku Heading to $395
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed
The post RNAZ Stock Alert: The Breast Cancer Study News Sending TransCode Therapeutics Soaring Today appeared first on InvestorPlace.
TransCode Therapeutics (NASDAQ:RNAZ) stock is rocketing higher on Thursday as investors react to positive news from a breast cancer study.
代码转换治疗学(纳斯达克:RNAZ)周四,随着投资者对一项乳腺癌研究的积极消息做出反应,股价飙升。
Source: Bukhta Yurii / Shutterstock.com
来源:Bukhta Yurii/Shutterstock.com
According to a press release from the company, preclinical trial data for TTX-MC138 shows that it could be an effective treatment of breast cancer. TTX-MC138 is an RNA therapeutics treatment in development from the company.
根据该公司的一份新闻稿,TTX-MC138的临床前试验数据表明,它可能是一种有效的乳腺癌治疗方法。TTX-MC138是该公司正在开发的RNA疗法。
Results from the preclinical study were published in Cancer Nanotechnology. It’s under the title “Radiolabeling and PET-MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastic lesions in a murine model of metastatic breast cancer.”
临床前研究的结果发表在癌症纳米技术。它的标题是“实验性癌症治疗药物MN-anti-miR10b的放射标记和PET-MRI微剂量,证明了在转移性乳腺癌的小鼠模型中,MN-anti-miR10b可以传递到转移的病变中。”
Michael Dudley, CEO of TransCode Therapeutics, said this in the release sending RNAZ stock higher today.
转码治疗公司首席执行官迈克尔·达德利在新闻稿中说,这推动RNAZ股价今天走高。
‘For TransCode, we believe this study further confirms the pharmacokinetic profile of TTX-MC138, supporting the viability of our platform for delivery of RNA-based therapy to metastatic solid tumors. Our preclinical data further suggest the therapeutic potential of TTX-MC138, and we look forward to our Phase 0 study which has the potential to establish clinical proof-of-concept for this therapy.”
在代码转换方面,我们相信这项研究进一步证实了TTX-MC138的药代动力学特征,支持了我们为转移性实体肿瘤提供基于RNA的治疗的平台的可行性。我们的临床前数据进一步表明了TTX-MC138的治疗潜力,我们期待着我们的0期研究,它有可能为这种疗法建立临床概念验证。“
So what does TransCode Therapeutics plan to do next? The company says it will file an exploratory investigational new drug application for TTX-MC138 in the first quarter of 2022. The goal is to use this for support of a Phase 0 study of its potential breast cancer treatment.
那么转码治疗公司下一步计划做什么呢?该公司表示,将在2022年第一季度为TTX-MC138提交探索性研究新药申请。我们的目标是利用这一点来支持对其潜在乳腺癌治疗的0期研究。
RNAZ stock is seeing heavy trading on today’s news. As of this writing, more than 147 million shares of the stock have changed hands. To put that in perspective, the company’s daily average trading volume is closer to 1.1 million shares.
受今日新闻影响,RNAZ股票交易量很大。截至撰写本文时,该股已有超过1.47亿股易手。相比之下,该公司的日均成交量接近110万股。
RNAZ stock was up 91.4% as of Thursday afternoon.
截至周四下午,RNAZ股价上涨了91.4%。
We’ve got more of the latest stock market news investors need to know about below!
下面是投资者需要了解的更多最新股市新闻!
InvestorPlace offers deep dives into the stock market daily to assist traders. Today’s no different with us covering what thas shares of Plug Power (NASDAQ:PLUG), Novavax (NASDAQ:NVAX), and Roku (NASDAQ:ROKU) on the move. You can get all those details from the following links!
More Thursday Stock Market News
更多周四股市新闻
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
在出版之日,威廉·怀特没有(直接或间接)持有本文所述证券的任何头寸。本文表达的观点是作者的观点,以InvestorPlace.com为准出版指南.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed
除了最罕见的例外,InvestorPlace不会发布关于市值低于1亿美元或每天交易量低于10万股的公司的评论。这是因为这些“廉价股”经常是诈骗艺术家和市场操纵者的游乐场。如果我们确实发布了可能受我们的评论影响的低成交量股票的评论,我们要求 InvestorPlace.com该书的作者披露了这一事实,并警告读者其中的风险。 更多阅读: 便士股票-如何在不上当的情况下获利
The post RNAZ Stock Alert: The Breast Cancer Study News Sending TransCode Therapeutics Soaring Today appeared first on InvestorPlace.
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧